Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

4,391 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial.
Lannfelt L, Blennow K, Zetterberg H, Batsman S, Ames D, Harrison J, Masters CL, Targum S, Bush AI, Murdoch R, Wilson J, Ritchie CW; PBT2-201-EURO study group. Lannfelt L, et al. Among authors: harrison j. Lancet Neurol. 2008 Sep;7(9):779-86. doi: 10.1016/S1474-4422(08)70167-4. Epub 2008 Jul 30. Lancet Neurol. 2008. PMID: 18672400 Clinical Trial.
PBT2 rapidly improves cognition in Alzheimer's Disease: additional phase II analyses.
Faux NG, Ritchie CW, Gunn A, Rembach A, Tsatsanis A, Bedo J, Harrison J, Lannfelt L, Blennow K, Zetterberg H, Ingelsson M, Masters CL, Tanzi RE, Cummings JL, Herd CM, Bush AI. Faux NG, et al. Among authors: harrison j. J Alzheimers Dis. 2010;20(2):509-16. doi: 10.3233/JAD-2010-1390. J Alzheimers Dis. 2010. PMID: 20164561 Free article. Clinical Trial.
Evaluating the effects of the novel GLP-1 analogue liraglutide in Alzheimer's disease: study protocol for a randomised controlled trial (ELAD study).
Femminella GD, Frangou E, Love SB, Busza G, Holmes C, Ritchie C, Lawrence R, McFarlane B, Tadros G, Ridha BH, Bannister C, Walker Z, Archer H, Coulthard E, Underwood BR, Prasanna A, Koranteng P, Karim S, Junaid K, McGuinness B, Nilforooshan R, Macharouthu A, Donaldson A, Thacker S, Russell G, Malik N, Mate V, Knight L, Kshemendran S, Harrison J, Hölscher C, Brooks DJ, Passmore AP, Ballard C, Edison P. Femminella GD, et al. Among authors: harrison j. Trials. 2019 Apr 3;20(1):191. doi: 10.1186/s13063-019-3259-x. Trials. 2019. PMID: 30944040 Free PMC article. Clinical Trial.
Assessing cognition and daily function in early dementia using the cognitive-functional composite: findings from the Catch-Cog study cohort.
Jutten RJ, Harrison JE, Lee Meeuw Kjoe PR, Ingala S, Vreeswijk R, van Deelen RAJ, de Jong FJ, Opmeer EM, Aleman A, Ritchie CW, Scheltens P, Sikkes SAM. Jutten RJ, et al. Among authors: harrison je. Alzheimers Res Ther. 2019 May 15;11(1):45. doi: 10.1186/s13195-019-0500-5. Alzheimers Res Ther. 2019. PMID: 31092277 Free PMC article.
The clinical promise of biomarkers of synapse damage or loss in Alzheimer's disease.
Colom-Cadena M, Spires-Jones T, Zetterberg H, Blennow K, Caggiano A, DeKosky ST, Fillit H, Harrison JE, Schneider LS, Scheltens P, de Haan W, Grundman M, van Dyck CH, Izzo NJ, Catalano SM; Synaptic Health Endpoints Working Group. Colom-Cadena M, et al. Among authors: harrison je. Alzheimers Res Ther. 2020 Mar 2;12(1):21. doi: 10.1186/s13195-020-00588-4. Alzheimers Res Ther. 2020. PMID: 32122400 Free PMC article. Review.
The Cognitive-Functional Composite is sensitive to clinical progression in early dementia: Longitudinal findings from the Catch-Cog study cohort.
Jutten RJ, Harrison JE, Brunner AJ, Vreeswijk R, van Deelen RAJ, de Jong FJ, Opmeer EM, Ritchie CW, Aleman A, Scheltens P, Sikkes SAM. Jutten RJ, et al. Among authors: harrison je. Alzheimers Dement (N Y). 2020 Apr 17;6(1):e12020. doi: 10.1002/trc2.12020. eCollection 2020. Alzheimers Dement (N Y). 2020. PMID: 32313832 Free PMC article.
4,391 results